Beximco Pharmaceuticals Limited

AIM:BXP Stock Report

Market Cap: UK£239.9m

Beximco Pharmaceuticals Past Earnings Performance

Past criteria checks 5/6

Beximco Pharmaceuticals has been growing earnings at an average annual rate of 9%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 13.4% per year. Beximco Pharmaceuticals's return on equity is 11.2%, and it has net margins of 13.3%.

Key information

9.0%

Earnings growth rate

9.0%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate13.4%
Return on equity11.2%
Net Margin13.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Beximco Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

AIM:BXP Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2444,9465,95711,3680
30 Jun 2444,3925,83011,1120
31 Mar 2443,0855,33010,8730
31 Dec 2341,6524,91610,7060
30 Sep 2340,6394,72010,4800
30 Jun 2339,2674,61410,2000
31 Mar 2337,9744,47710,0330
31 Dec 2237,3794,6299,5920
30 Sep 2235,9875,1059,4630
30 Jun 2234,6695,1239,1010
31 Mar 2233,6605,7388,8870
31 Dec 2132,0626,0978,3930
30 Sep 2131,0375,5197,8370
30 Jun 2129,4945,1287,4700
31 Mar 2128,2694,5786,9180
31 Dec 2027,5174,0176,8020
30 Sep 2026,2353,7246,5810
30 Jun 2025,6123,5156,4510
31 Mar 2025,0563,4056,2210
31 Dec 1924,2023,2516,0680
30 Sep 1923,7353,1435,9000
30 Jun 1922,8173,0335,6890
31 Mar 1921,7242,8525,4700
31 Dec 1820,1882,7085,0530
30 Sep 1818,8232,6474,6610
30 Jun 1817,7172,5374,3560
31 Mar 1816,9242,5134,1590
31 Dec 1716,5172,4314,0540
30 Sep 1716,0222,3563,9830
30 Jun 1715,5092,2273,8290
31 Mar 1714,6872,2243,4800
31 Dec 1614,2712,1333,3900
30 Sep 1613,7362,0603,3420
30 Jun 1613,3561,9653,2630
31 Dec 1512,9661,9543,2660
30 Sep 1512,5731,8043,0820
30 Jun 1512,1341,8132,9920
31 Mar 1511,6281,6052,8670
31 Dec 1411,2071,5282,7550
30 Sep 1411,1391,4762,8060
30 Jun 1410,8471,4712,7320
31 Mar 1410,8041,4522,6860
31 Dec 1310,4911,4052,6190

Quality Earnings: BXP has high quality earnings.

Growing Profit Margin: BXP's current net profit margins (13.3%) are higher than last year (11.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BXP's earnings have grown by 9% per year over the past 5 years.

Accelerating Growth: BXP's earnings growth over the past year (26.2%) exceeds its 5-year average (9% per year).

Earnings vs Industry: BXP earnings growth over the past year (26.2%) exceeded the Pharmaceuticals industry 9.5%.

Return on Equity

High ROE: BXP's Return on Equity (11.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:33
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beximco Pharmaceuticals Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Md. IslamBRAC EPL Stock Brokerage Ltd
Asif KhanEDGE Research & Consulting
Lorenza CastellonEquity Development Limited